Sanofi Hits M&A Trail Again To Buy UK's KyMab
Gets Hold Of Gets Mid-Stage Atopic Dermatitis Drug
Executive Summary
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
You may also be interested in...
Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
Sanofi Nabs Priority Review For New Pompe Drug
The French drugmaker's follow up to Myozyme – avalglucosidase alfa – is in line for a potential US approval by May next year after the US FDA agreed to a speedy review of the enzyme replacement therapy, unlike its European counterparts.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports